Evaluate the impact of increasing operational flow rate steps (e.g. equilibrations, washes, and clean-in-place (CIP)) on the overall productivity (mg mAb/hour) of GORE Protein Capture Devices (PROA101 & PROA102).
ViaCyte, Inc. and W. L. Gore & Associates, Inc. today announced a $10 million investment by Gore into ViaCyte in the form of a
convertible promissory note. This new investment by Gore into ViaCyte follows a similar multimillion‐dollar investment by Gore in May 2017.